MedTrace Logo

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

NCT01245803 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2010-11-23

No results posted yet for this study

Summary

Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

Conditions

  • Acute Coronary Syndrome
  • Angioplasty

Interventions

DRUG

additional rosuvastatin loading

additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI

DRUG

placebo control

sugar pill is given 18-24hr and 4-6hr before PCI as control

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-04-30
Completion
2011-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245803 on ClinicalTrials.gov